BPC-157
Body Protection Compound-157 / Pentadecapeptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It's one of the most talked-about research peptides for soft-tissue repair — studied for tendon, ligament, muscle, gut and nerve healing. This guide breaks down how BPC-157 actually works, what the research does and doesn't show, how it's dosed in the literature, its safety profile and legal status, and how it compares to TB-500 — honestly, without the hype.
BPC-157 quick facts
| Reported research dosing | 250mcg-1mg |
| Route | Subq |
| Cycle length | 4-12 Weeks |
| Frequency | 1-2x Daily Am and PM · 5 On 2 Off or Daily |
| Half-life | ~4 hrs systemic (longer locally) |
| Forms | Injectable, Oral, Nasal |
| Evidence level | Strong animal + heavy anecdotal; limited human |
The go-to recovery peptide. Run it near the injury when you can; consistency beats megadosing.
How BPC-157 works
BPC-157's headline mechanism is angiogenesis — the growth of new blood vessels into damaged tissue. In research models it upregulates vascular endothelial growth factor (VEGF) and activates the VEGFR2 receptor, kicking off the PI3K/Akt and MAPK/ERK signaling cascades that drive new capillary formation. More blood vessels means more oxygen, nutrients and repair cells reaching an injury.
It also acts fast on the nitric-oxide (NO) system. Studies show BPC-157 phosphorylates endothelial nitric oxide synthase (eNOS) within about 30 minutes and disrupts the Cav-1–eNOS inhibitory complex, directly increasing nitric-oxide production in a dose-dependent way — which supports blood flow and vascular tone.
At the tissue level, BPC-157 has been shown to upregulate the growth-hormone receptor in tendon fibroblasts and to boost collagen synthesis and fibroblast activity. In a rat Achilles-tendon model it produced a ~2.3-fold increase in vascular density in the repair zone by day 14. Together these effects explain why it's researched across tendon, ligament, muscle, bone and gut tissue.
What the research shows — benefits by use case
Tendon, ligament & joint. The strongest preclinical signal. Animal models show faster, stronger tendon-to-bone and ligament healing, and a small human pilot in knee pain reported meaningful relief. This is the use case BPC-157 is best known for.
Gut & GI. BPC-157 originates from gastric juice, and much of its earliest research is on the gut — protecting against ulcers, supporting intestinal-barrier integrity ('leaky gut'), and healing GI lesions in animal models. This is why it's frequently used orally for gut goals.
Muscle & nerve. Preclinical work suggests accelerated muscle-crush recovery and peripheral-nerve regeneration, likely downstream of the same angiogenic and growth-factor effects.
Important honesty check: the overwhelming majority of this evidence is from animal studies. It's promising and mechanistically coherent, but it is not the same as proven human efficacy — see the next section.
The honest state of human evidence
Despite decades of striking animal data, robust human evidence for BPC-157 is still very thin. As of 2026 only a handful of small human pilot studies have been published — on the order of a few dozen total subjects — covering interstitial cystitis (bladder), knee pain, and an early IV-safety study. A larger Phase I trial begun in 2015 was never published.
Bottom line: BPC-157 is a genuinely promising research compound, not a proven therapy. Anyone considering it should treat it as experimental and weigh that limited human data honestly.
BPC-157 dosing (research reference)
Across the research and practitioner literature, BPC-157 is most commonly referenced in the 250 mcg–1 mg per day range, often split into one or two doses and run in cycles of roughly 4–12 weeks. Injectable (subcutaneous) is the most studied route, frequently placed near the site of injury; oral is popular specifically for gut-related goals, and nasal forms also exist.
BPC-157 ships as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Use the reconstitution calculator above to convert your vial size and target dose into exact insulin-syringe units. None of this is dosing advice — it's a summary of what the research references, for educational purposes only.
Safety & side effects
In the animal literature and the small human pilots to date, BPC-157 has generally been reported as well tolerated, with few acute side effects noted. That said, the honest caveat is we lack long-term human safety data. Because its core mechanism is angiogenesis, there is a theoretical discussion around whether promoting blood-vessel growth is desirable in every individual context. Product quality also varies widely in the research-chemical market — purity, correct sequence and sterility are real concerns, so third-party testing and a Certificate of Analysis matter.
BPC-157 vs TB-500 — and stacking
BPC-157 and TB-500 are the two pillars of the 'healing peptide' world and are often discussed together. BPC-157 leans toward local, vascular and gut repair via VEGF and nitric oxide; TB-500 (a fragment of thymosin beta-4) works more systemically by regulating actin to drive cell migration and flexibility. Many protocols run them together — that combination is the basis of the popular Wolverine blend — on the theory that they hit complementary arms of the healing process.
Legal & regulatory status
In 2023 the FDA placed BPC-157 in Category 2 of its bulk-drug-substance review, meaning it cannot currently be legally compounded by pharmacies for human use — citing limited safety data and manufacturing/immunogenicity concerns. Its status remains under active review. For that reason BPC-157 is sold and discussed as a research compound (research use only), not an approved medicine. Always follow the laws in your jurisdiction.
✅ Clinically validated
- No completed randomised human trial, and it is worth being exact about why. BPC-157 is a synthetic fragment of a gastric protein; it has no patentable composition worth the cost of a phase 3, and no sponsor has taken one on. A trial has been registered but there is no published human efficacy result.
- The FDA moved it to the bulk-substances category 2 list in 2023, which restricts compounding — a regulatory judgement about the absence of data, not a finding of harm.
📊 Correlative data
- One of the most-used peptides in existence and the anecdotal record is correspondingly enormous, particularly for tendon, ligament and gut complaints. It is also the clearest case in the Vault of why anecdote is a weak instrument: soft-tissue injuries and gut flares both improve on their own, so a compound taken during recovery gets the credit either way.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 Theoretical / extrapolated
- The animal literature is unusually broad and unusually consistent — accelerated tendon-to-bone healing, protection against NSAID-induced gut damage, and effects on the nitric-oxide system across many rodent models from largely one research group.
- The proposed mechanism is upregulation of VEGF-driven angiogenesis and growth-factor receptor expression at the injury site. That same angiogenic mechanism is the reason for the one caution that actually matters here: anything that reliably grows new blood vessels is a question mark in the presence of an undiagnosed tumour, and nobody has studied that in humans.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
BPC-157 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signalling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumour needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterised. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
BPC-157 reconstitution calculator
Research reconstitution calculator
Where to get BPC-157
Buy BPC-157 at AminoWell USA →BPC-157 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What BPC-157 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for BPC-157 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
Bloodwork to run alongside BPC-157
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation, so you can tell recovery from placebo |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney before anything injectable |
| Complete Blood Count (CBC) with Differential | Infection and platelet baseline |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 102 markers A–Z
BPC-157 — frequently asked questions
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It's researched primarily for soft-tissue repair — tendon, ligament, muscle, gut and nerve healing.
How does BPC-157 work?
Its main studied mechanism is angiogenesis — it upregulates VEGF and activates the VEGFR2/PI3K-Akt pathway to grow new blood vessels, and it rapidly boosts nitric-oxide production via eNOS. It also increases collagen synthesis and growth-hormone-receptor expression in tendon fibroblasts.
Does BPC-157 actually work in humans?
Most evidence is from animal studies and is promising. Human data is still very limited — only a few small pilot studies (knee pain, interstitial cystitis, IV safety) totaling a few dozen subjects. Treat it as an experimental research compound, not a proven therapy.
Is BPC-157 FDA-approved or legal?
BPC-157 is not FDA-approved. In 2023 the FDA placed it in Category 2, meaning it can't be legally compounded for human use, and its status remains under review. It's sold as a research compound (research use only). Follow the laws in your area.
How is BPC-157 dosed?
The research literature most commonly references 250 mcg–1 mg per day, often split and cycled over 4–12 weeks. Injectable (subcutaneous, often near the injury) is most studied; oral is popular for gut goals. It's reconstituted with bacteriostatic water — use the calculator above. This is educational, not dosing advice.
Oral vs injectable BPC-157 — what's the difference?
Injectable (subcutaneous) is the most-studied route and is typically chosen for systemic or localized tendon/ligament goals. Oral BPC-157 is popular specifically for gut and GI goals, since the peptide originates from gastric juice and acts locally in the digestive tract.
BPC-157 vs TB-500 — which is better?
They do different jobs and are often combined. BPC-157 focuses on local vascular and gut repair; TB-500 works more systemically on cell migration and flexibility. Many people stack them (the 'Wolverine' blend) rather than choosing one.
What are the side effects of BPC-157?
In animal studies and small human pilots it's generally reported as well tolerated, but long-term human safety data is lacking. Because it promotes blood-vessel growth, that mechanism is worth understanding, and product purity in the research market varies — insist on third-party testing.
How long does BPC-157 take to work?
There's no established human timeline. Anecdotal and preclinical reports vary from days to several weeks depending on the tissue and goal, which is why cycles are often referenced in the 4–12 week range. Individual results are unproven and vary.
References & further reading
- BPC-157 molecular mechanisms — cytoprotection, angiogenesis & nitric oxide (PMC, 2025)
- BPC-157 and the Src–Caveolin-1–eNOS nitric-oxide pathway (PMC)
- BPC-157 enhances growth-hormone-receptor expression in tendon fibroblasts (PMC)
- BPC-157 human clinical trials — status & results (Peptide Database)
- Legal status of BPC-157 in compounding & clinical practice (regulatory alert)
Want Coach Cam's exact BPC-157 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What BPC-157 is used for
BPC-157 appears under 5 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.